Zulian F, Cuffaro G, SperottoF. Scleroderma in children: an update. Curr Opin Rheumatol. 2013;25(5):643-50.

https://doi.org/10.1097/BOR.0b013e3283641f61

Arango C, Malagón C, Gómez M, Mosquera C, Yépez R, González T, et al. Esclerodermia localizada juvenil: ¿es una enfermedad benigna? Rev Colomb Reumatol. 2017;24(3):129-96. http://dx.doi.org/10.1016/j.rcreu.2017.02.006.

https://doi.org/10.1016/j.rcreu.2017.02.006

Fett N, Werth VP. Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2011;64(2):217-28; quiz 229-30.

https://doi.org/10.1016/j.jaad.2010.05.045

Torok K. Pediatric scleroderma: systemic or localized forms. Pediatr Clin North Am. 2012;59(2):381-405.

https://doi.org/10.1016/j.pcl.2012.03.011

Laxer RM, Zulian F. Localized scleroderma. Curr Opin Rheumatol. 2006;18(6):606-13.

https://doi.org/10.1097/01.bor.0000245727.40630.c3

Yaqub A, Chung L, Rieger KE, Fiorentino DF. Localized cutaneous fibrosing disorders. Rheum Dis Clin North Am. 2013;39(2):347-64.

https://doi.org/10.1016/j.rdc.2013.02.013

Bielsa Marsol I. Update on the classification and treatment of localized scleroderma. Actas Dermosifiliogr. 2013;104(8):654-66.

https://doi.org/10.1016/j.ad.2012.10.003

Tollefson MM, Witman PM. En coup de sabre morphea and Parry-Romberg syndrome: A retrospective review of 54 patients. J Am Acad Dermatol. 2007;56(2):257-63.

https://doi.org/10.1016/j.jaad.2006.10.959

Chiu YE, Vora S, Kwon EK, Maheshewari M. A significant proportion of children with morphea en coup de sabre and Parry-Romberg syndrome have neuroimaging findings. Pediatr Dermatol. 2012;29(6):738-48.

https://doi.org/10.1111/pde.12001

Li SC. Scleroderma in Children and Adolescents: Localized Scleroderma and Systemic Sclerosis. Pediatr Clin North Am. 2018;65(4):757-81.

https://doi.org/10.1016/j.pcl.2018.04.002

Leitenberger JJ, Cayce RL, Haley RW, AdamsHuet B, Bergstresser PR, Jacobe HT. Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases. Arch Dermatol. 2009;145(5):545-50.

https://doi.org/10.1001/archdermatol.2009.79

Galán M, Rodríguez A, Vázquez MC, Jiménez R, Collantes E, Moreno JC. Morfea panesclerótica discapacitante de la infancia: un nuevo caso. Med Cutan Iber Lat Am. 2009;37:175-9.

Zulian F, Vallongo C, Woo P, Russo R, Ruperto N, Harper J, et al. Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum. 2005;52(9):2873-81.

https://doi.org/10.1002/art.21264

Lis-Święty A, Janicka I, Skrzypek-Salamon A, Brzezińska-Wcisło L. A systematic review of tools for determining activity of localized scleroderma in paediatric and adult patients. J Eur Acad Dermatol Venereol. 2017;31(1):30-7.

https://doi.org/10.1111/jdv.13790

Takehara K, Sato S. Localized scleroderma is an autoimmune disorder. Rheumatology. 2005;44(3):274-9.

https://doi.org/10.1093/rheumatology/keh487

Takehara K, Kikuchi K, Soma Y, Igarashi A, Ishibashi Y. Anti-single-stranded DNA antibody and muscle involvement in localized scleroderma. Arch Dermatol. 1990;126(10):1368.

https://doi.org/10.1001/archderm.1990.01670340120025

Sato S, Fujimoto M, Ihn H, Kikuchi K, Takehara K. Clinical characteristics associated with antihistone antibodies in patients with localized scleroderma. J Am Acad Dermatol.1994;31(4):567-71.

https://doi.org/10.1016/S0190-9622(94)70217-9

Careta MF, Romiti R. Localized scleroderma: clinical spectrum and therapeutic update. An Bras Dermatol. 2015;90(1):62-73.

https://doi.org/10.1590/abd1806-4841.20152890

Hulshof MM, Bouwes Bavinck JN, Bergman W, Masclee AA, Heickendorff L, Breedveld FC, et al. Doubleblind, placebocontrolled study of oral calcitriol for the treatment of localized and systemic scleroderma. J Am Acad Dermatol. 2000;43(6):1017-23.

https://doi.org/10.1067/mjd.2000.108369

Kroft EB, Groeneveld TJ, Seyger MM, de Jong EM. Efficacy of topical tacrolimus 0.1% in active plaque morphea: randomized, double-blind, emollient-controlled pilot study. Am J Clin Dermatol. 2009;10(3):181-7.

https://doi.org/10.2165/00128071-200910030-00004

Joly P, Bamberger N, Crickx B, Belaich S. Treatment of severe forms of localized scleroderma with oral corticosteroids: follow-up study on 17 patients. Arch Dermatol. 1994;130(5):663-4.

https://doi.org/10.1001/archderm.1994.01690050133027

Amy de la Bretèque AM, Rybojad M, Cordoliani F, Petit A, Juillard C, Flageul B, et al. Relapse of severe forms of adult morphea after oral corticosteroid treatment. J Eur Acad Dermatol Venereol. 2013;27(9):1190-1.

https://doi.org/10.1111/jdv.12039

Zulian F, Vallongo C, Patrizi A, Belloni-Fortina A, Cutrone M, Alessio M, et al. A longterm followup study of methotrexate in juvenile localized scleroderma (morphea). J Am Acad Dermatol. 2012;67(6):1151-6.

https://doi.org/10.1016/j.jaad.2012.03.036

Martini G, Ramanan AV, Falcini F, Girschick H, Goldsmith DP, Zulian F. Successful treatment of severe or methotrexate-resistant juvenile localized scleroderma with mycophenolate mofetil. Rheumatology. 2009;48(11):1410-3.

https://doi.org/10.1093/rheumatology/kep244

Sunderkötter C, Kuhn A, Hunzelmann N, Beissert S. Phototherapy: a promising treatment option for skin sclerosis in scleroderma? Rheumatology. 2006;45:52-4.

https://doi.org/10.1093/rheumatology/kel293

Lott AM, Robles MB, Marrou Wr. Transferencia de grasa autóloga en esclerodermia localizada y multicéntrica. Cir Plast Iberolatinoam. 2016;42:285-92.